//www.makeeyeware.comInsight
//www.makeeyeware.comTaplow
//www.makeeyeware.comKnowledge
  • News
  • Cases
  • Downloads
The Taplow Group – Global Business Report - March 2021
16.03.2021

The Taplow Group – Global Business Report - March 2021

The Taplow Group S.A. with 21 partner firms has its presence across 6 continents. Our expert consultants not only bring a wealth of expertise in...
The Taplow Group S.A. 2020 Financial Report
15.03.2021

The Taplow Group S.A. 2020 Financial Report

The Taplow Group S.A., A leading Global Executive Search, Human Capital, Board Advisory and Interim Executive company with 21 partner...
Taplow Group – Pandemic Business Overview – February 2021
15.02.2021

Taplow Group – Pandemic Business Overview – February 2021

全球大流行企业影响cross every sector, in all parts of the world. Taplow partners across the globe have combined to...
1 2 3 4 5 6 7 8 9 10 Last

首席执行官的运动:

Situation: A Finnish, mainly nationally operating sports company needed new CEO as the old one was about to retire. As sports business is one of the competence areas of our Finnish partner, we ended up delivering this search.

Read more …

For further Information please contacTimo Toivanen, Finland

CEO FOR LOGISTICS:

Situation: One of the largest globally operating Logistics companies was in a need of new CIO for Finland. As Logistics and Value Chain is one of the competence areas of our Finnish partner, we ended up delivering this search.

Read more …

For further Information please contacTimo Toivanen, Finland

White Papers
  • India – The new R&D hub for Automotive

    Taplow India have conducted an in-depth review of the Automotive sector in India, For further information contactSangeeta Sabharwal, India

    Click Here
  • Maysam Rizvi reviews the Banking Tech Revolution.

    Capital is more expensive, costs are higher and prices have gone down… the technology revolution has become a necessity.

    Click Here
  • EVOLVING BUSINESS UNITS Market Access thus becoming “transversal”

    The pharmaceutical market, in regards to the price component covered by the NHS, has been, until today, characterised by the presence of drugs of high therapeutic value, such as cancer-drugs, rheumatologic drugs, anti-infection drugs and drugs for the treatment of chronic illnesses, the vast majority of which have either seen their patent expire recently or will see it expire in the next two years.

    Click Here
  • BUSINESS CYCLES

    Present Human Capital Opportunities and Challenges:

    Click Here